Thomas E. Stinchcombe, MD
Dr. Thomas E. Stinchcombe is a medical oncologist at the Duke Cancer Institute and a Professor of Medicine at the Duke School of Medicine in Durham, North Carolina. He specializes in the treatment of thoracic malignancies, including small and non-small cell lung cancer and malignant pleural mesothelioma. [1]
Dr. Stinchcombe is actively involved in the development and application of new therapies for the treatment of these conditions. He prioritizes explaining his diagnosis to patients to make sure that they understand their prognosis and their options. He is excited by the promise of new therapies like molecular therapy and immunotherapy.
Education and Career
Dr. Stinchcombe earned his medical degree at the University of Virginia School of Medicine in Charlottesville, Virginia, and then completed his internship and residency in Internal Medicine at the University of Michigan in Ann Arbor, Michigan. He completed a fellowship in Hematology and Oncology at the University of North Carolina in Chapel Hill, North Carolina.[1]
After completing his training, Dr. Stinchcombe was director of the thoracic medical oncology program and Co-Director of the Multidisciplinary Thoracic Oncology Program of the Lineberger Comprehensive Cancer Center at the University of North Carolina. He was recruited to the Duke Cancer Institute to serve as Professor of Medicine in Medical Oncology and to help lead the thoracic oncology group in the Solid Tumor Therapeutics Program.[3]
Research
Dr. Stinchcombe’s research focus is on clinical trials to develop new therapies for the treatment of small cell and non-small cell lung cancer, as well as malignant pleural mesothelioma. He is particularly interested in the role of molecular therapy and immunotherapy in the cancer disease process. He enjoys bringing promising new therapies to the clinic.[1]
Dr. Stinchcombe’s recent publications include:[2]
Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-… Wang, X., Damman, B., Mentlick, J., Wigle, D., Jones, D., Conti, M., Ashrafi, A., Liberman, M., de Perrot, M., Mitchell, J., Keenan, R., Bauer, T., Miller, D., Stinchc…>; Journal of Clinical Oncology. 2024 Jan 12
Convolutional Neural Networks for Segmentation of Malignant Pleural Mesothelioma: Analysis of Probability Map Thresholds (CALGB 30901, Alliance). Shenouda, M., Gudmundsson, E., Li, F., Wang, X., Starkey, A., Armato, S., Straus, C., Kindler, H., Dudek, A., Stinchcombe, T.> ;Arxiv. 2023 Nov 30
Enrollment Success, Factors, and Prediction Models in Cancer Trials (2008-2019). Siqi Zhang, Jianrong Zhang, Sida Liu, Herbert Pang, Thomas E Stinchcombe, Xiaofei Wang>;JCO Oncology Practice. 2023 Nov 1
